93 related articles for article (PubMed ID: 28650526)
1. A Dual-Administration Microtracer Technique to Characterize the Absorption, Distribution, Metabolism, and Excretion of [
Helmer E; Nicolas JM; Long J; Roffel AF; Jones E; Chanteux H; Diaz N; Garratt H; Bosje T
J Clin Pharmacol; 2017 Dec; 57(12):1582-1590. PubMed ID: 28650526
[TBL] [Abstract][Full Text] [Related]
2. Role of P-glycoprotein in the brain disposition of seletalisib: Evaluation of the potential for drug-drug interactions.
Nicolas JM; Chanteux H; Nicolaï J; Brouta F; Viot D; Rosseels ML; Gillent E; Bonnaillie P; Mathy FX; Long J; Helmer E
Eur J Pharm Sci; 2020 Jan; 142():105122. PubMed ID: 31678424
[TBL] [Abstract][Full Text] [Related]
3. A double-tracer technique to characterize absorption, distribution, metabolism and excretion (ADME) of [
Guerini E; Schadt S; Greig G; Haas R; Husser C; Zell M; Funk C; Hartung T; Gloge A; Mallalieu NL
Xenobiotica; 2017 Feb; 47(2):144-153. PubMed ID: 27123695
[TBL] [Abstract][Full Text] [Related]
4. First-in-human studies of seletalisib, an orally bioavailable small-molecule PI3Kδ inhibitor for the treatment of immune and inflammatory diseases.
Helmer E; Watling M; Jones E; Tytgat D; Jones M; Allen R; Payne A; Koch A; Healy E
Eur J Clin Pharmacol; 2017 May; 73(5):581-591. PubMed ID: 28160012
[TBL] [Abstract][Full Text] [Related]
5. Characterization of Clinical Absorption, Distribution, Metabolism, and Excretion and Pharmacokinetics of Velsecorat Using an Intravenous Microtracer Combined with an Inhaled Dose in Healthy Subjects.
Holmberg AA; Weidolf L; Necander S; Bold P; Sidhu S; Pelay-Gimeno M; de Ligt RAF; Verheij ER; Jauhiainen A; Psallidas I; Wählby Hamrén U; Prothon S
Drug Metab Dispos; 2022 Feb; 50(2):150-157. PubMed ID: 34853068
[TBL] [Abstract][Full Text] [Related]
6. The Absolute Bioavailability and Absorption, Metabolism, and Excretion of Ipatasertib, a Potent and Highly Selective Protein Kinase B (Akt) Inhibitor.
Takahashi RH; Malhi V; Liederer BM; Cho S; Deng Y; Dean B; Nugteren J; Yost E; Al-Sayah MA; Sane R; Kshirsagar S; Ma S; Musib L
Drug Metab Dispos; 2023 Oct; 51(10):1332-1341. PubMed ID: 37524543
[TBL] [Abstract][Full Text] [Related]
7. An Innovative Approach to Characterize Clinical ADME and Pharmacokinetics of the Inhaled Drug Nemiralisib Using an Intravenous Microtracer Combined with an Inhaled Dose and an Oral Radiolabel Dose in Healthy Male Subjects.
Harrell AW; Wilson R; Man YL; Riddell K; Jarvis E; Young G; Chambers R; Crossman L; Georgiou A; Pereira A; Kenworthy D; Beaumont C; Marotti M; Wilkes D; Hessel EM; Fahy WA
Drug Metab Dispos; 2019 Dec; 47(12):1457-1468. PubMed ID: 31649125
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics, Excretion, and Mass Balance of [
Ambery C; Young G; Fuller T; Lazaar AL; Pereira A; Hughes A; Ramsay D; van den Berg F; Daley-Yates P
Clin Pharmacol Drug Dev; 2018 Nov; 7(8):901-910. PubMed ID: 30230263
[TBL] [Abstract][Full Text] [Related]
9. Differential pharmacokinetics of diclofenac potassium for oral solution vs immediate-release tablets from a randomized trial: effect of fed and fasting conditions.
Chen C; Bujanover S; Kareht S; Rapoport AM
Headache; 2015 Feb; 55(2):265-75. PubMed ID: 25546369
[TBL] [Abstract][Full Text] [Related]
10. Seletalisib: Characterization of a Novel, Potent, and Selective Inhibitor of PI3K
Allen RA; Brookings DC; Powell MJ; Delgado J; Shuttleworth LK; Merriman M; Fahy IJ; Tewari R; Silva JP; Healy LJ; Davies GCG; Twomey B; Cutler RM; Kotian A; Crosby A; McCluskey G; Watt GF; Payne A
J Pharmacol Exp Ther; 2017 Jun; 361(3):429-440. PubMed ID: 28442583
[TBL] [Abstract][Full Text] [Related]
11. Mass Balance and Absorption, Distribution, Metabolism, and Excretion Properties of Balcinrenone following Oral Administration in Combination with Intravenous Microtracer in Healthy Subjects.
Lindmark B; Li XQ; Bhattacharya C; Housler G; Heijer M; Bragg RA; Gränfors M; Pelay-Gimeno M; Vaes WHJ; Menakuru S; Pizzato PE; Ericsson H; Johansson S
Drug Metab Dispos; 2023 Aug; 51(8):995-1004. PubMed ID: 37407094
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of methylphenidate after oral administration of two modified-release formulations in healthy adults.
Markowitz JS; Straughn AB; Patrick KS; DeVane CL; Pestreich L; Lee J; Wang Y; Muniz R
Clin Pharmacokinet; 2003; 42(4):393-401. PubMed ID: 12648029
[TBL] [Abstract][Full Text] [Related]
13. Relative bioavailability and pharmacokinetics of a new sibutramine formulation in healthy male subjects: a randomized, open-label, two-period, comparative crossover study.
Park JY; Kim KA; Park PW; Suh KH; Lee GS
Clin Ther; 2004 Dec; 26(12):2092-101. PubMed ID: 15823773
[TBL] [Abstract][Full Text] [Related]
14. Rilzabrutinib, a reversible covalent Bruton's tyrosine kinase inhibitor: Absorption, metabolism, excretion, and absolute bioavailability in healthy participants.
Ucpinar S; Smith PF; Long L; Li F; Yan H; Wadhwa J; Chu KA; Shu J; Nunn P; Li M
Clin Transl Sci; 2023 Jul; 16(7):1210-1219. PubMed ID: 37060187
[TBL] [Abstract][Full Text] [Related]
15. Investigation of Clinical Absorption, Distribution, Metabolism, and Excretion and Pharmacokinetics of the HIV-1 Maturation Inhibitor GSK3640254 Using an Intravenous Microtracer Combined with EnteroTracker for Biliary Sampling.
Wen B; Zhang Y; Young GC; Kenworthy D; Pereira A; Pirhalla J; Doyle J; Jordon B; Zhan J; Johnson M
Drug Metab Dispos; 2022 Nov; 50(11):1442-1453. PubMed ID: 36153007
[TBL] [Abstract][Full Text] [Related]
16. Bioavailability of two oral-tablet and two oral-suspension formulations of naproxen sodium/paracetamol (acetaminophen): single-dose, randomized, open-label, two-period crossover comparisons in healthy Mexican adult subjects.
Palma-Aguirre JA; Villalpando-Hernández J; Novoa-Heckel G; Oliva I; Cariño L; López-Bojórquez E; Burke-Fraga V; Namur S; González-de la Parra M
Clin Ther; 2009 Feb; 31(2):399-410. PubMed ID: 19302912
[TBL] [Abstract][Full Text] [Related]
17. Oral bioavailability and disposition of [14C]omapatrilat in healthy subjects.
Malhotra BK; Iyer RA; Soucek KM; Behr D; Liao WC; Mitroka JG; Kaul S; Cohen MB; Knupp CA
J Clin Pharmacol; 2001 Aug; 41(8):833-41. PubMed ID: 11504270
[TBL] [Abstract][Full Text] [Related]
18. Bioavailability of two sublingual formulations of ketorolac tromethamine 30 mg: a randomized, open-label, single-dose, two-period crossover comparison in healthy Mexican adult volunteers.
Galán-Herrera JF; Poo JL; Maya-Barrios JA; de Lago A; Oliva I; González-de la Parra M; Jiménez P; López-Bojórquez E; Burke-Fraga V; Namur S
Clin Ther; 2008 Sep; 30(9):1667-74. PubMed ID: 18840372
[TBL] [Abstract][Full Text] [Related]
19. Absolute and relative bioavailability of the HMG-CoA reductase inhibitor cerivastatin.
Mück W; Ritter W; Ochmann K; Unger S; Ahr G; Wingender W; Kuhlmann J
Int J Clin Pharmacol Ther; 1997 Jun; 35(6):255-60. PubMed ID: 9208342
[TBL] [Abstract][Full Text] [Related]
20. Absorption, distribution, metabolism, and excretion (ADME) of ¹⁴C-sonidegib (LDE225) in healthy volunteers.
Zollinger M; Lozac'h F; Hurh E; Emotte C; Bauly H; Swart P
Cancer Chemother Pharmacol; 2014 Jul; 74(1):63-75. PubMed ID: 24817600
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
